Medicamen Biotech Q2 FY27: consolidated PAT surges 95% YoY on sharp margin expansion
PAT +94.8% YoY · revenue +16.25% · margins expanding
₹54.83 Cr
+16.25% YoY
₹4.12 Cr
+94.8% YoY
7.51%
+3.1pp YoY
₹3.04
Medicamen Biotech's consolidated revenue rose 16.25% YoY to ₹54.83 Cr (from ₹47.17 Cr) and 14.48% QoQ (from ₹47.90 Cr), while consolidated PAT for the period jumped 94.8% YoY to ₹4.12 Cr (from ₹2.11 Cr) and 123.1% QoQ (from ₹1.85 Cr). Profit attributable to the parent's shareholders was ₹3.41 Cr, versus standalone-only PAT of ₹2.35 Cr — the gap reflects contributions from wholly-owned subsidiary Opal Pharmaceuticals and domestic subsidiary Medicamen Life Sciences, whose minority share flipped to a ₹0.71 Cr profit this quarter from a ₹0.27 Cr loss in Q1 FY27. Both margins expanded materially: operating margin (EBITDA/revenue) widened to 15.84% from 10.93% a year ago and 9.03% last quarter, while net margin rose to 7.51% from 4.45% YoY. No exceptional items appear in the current or comparative quarters, so this growth is on a clean, unadjusted basis.
Q2 FY-2027 vs prior quarters
The margin expansion is driven primarily by a lower combined raw-material-and-inventory cost ratio — about 40% of revenue this quarter versus roughly 49% a year ago — partly offset by other expenses rising to 26.5% of revenue from 21.1% YoY. There is no prior management guidance on record, and a web search found no broker consensus or estimate for this quarter from any covering analyst, so vsGuidance and vsStreet are marked unknown rather than inferred. Among the quarter's corporate developments, Shivalik Rasayan acquired a 3.56% stake in the company on October 26, 2026, and the company allotted 5 lakh shares on warrant conversion on October 23, 2026 — both after quarter-end and not yet reflected in the September 30, 2026 balance sheet, where equity share capital is unchanged at ₹13.56 Cr. No management press release accompanying this result was available to cross-check against the reported numbers.
The stock went into the print at ₹278.5, down 5.9% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
W1
Raw-material/inventory cost ratio sustainability — currently ~40% of revenue vs ~49% a year ago
W2
Medicamen Life Sciences subsidiary's minority profit (₹0.71 Cr this quarter vs a ₹0.27 Cr loss in Q1 FY27) — watch if it holds
W3
Shivalik Rasayan's 3.56% stake acquisition (Oct 26, 2026) — watch for any further stake build-up or strategic disclosures